Phase 2
Completed N=39
Candin Safety & Efficacy Study for the Treatment of Warts
Warts · Human Papilloma Virus
Source: ClinicalTrials.gov NCT01757392 ↗
Enrolled (actual)
39
Serious AEs
2.9%
Results posted
Jan 2021
Primary outcomePrimary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants
Summary
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Complete Resolution of Primary Injected Wart |
19 | — |
| SECONDARY Number of Participants With Complete Resolution of the Primary Injected Wart by Number of Injection Visits |
5; 4; 3; 4; 1; 2 | — |
Eligibility Criteria
Inclusion Criteria
- Must have at least 3 and not more than 10 common warts not located on the palms or digits
- Positive DTH response to Candin® required
Exclusion Criteria
- No previous medical treatment for warts other than OTC
- No immunocompromising medical conditions or medicines allowed
- No preexisting inflammatory conditions at treatment site allowed
Data sourced from ClinicalTrials.gov (NCT01757392). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.